Mission Therapeutics appoints Anker Lundemose as Chief Executive Officer
Mission Therapeutics announced the appointment of Dr Anker Lundemose MD PhD as Chief Executive Officer.
Dr Lundemose brings extensive experience to Mission at a pivotal stage in the Company’s evolution, as it transitions from discovery to development. In a biopharma career spanning over two and a half decades, he was most recently CEO of Norwegian vaccine company Bionor Pharma ASA, and previously co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, subsequently reversed into OSI. The Mission appointment constitutes Dr Lundemose’s fourth CEO position. As a CEO, Executive Vice President, co-founder and/or board member, he has been involved in a total of six biotech exits/IPOs.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.